BMS Strengthens Neuroscience Portfolio with Karuna Therapeutics Acquisition
Bristol Myers Squibb (BMS) has announced the completion of its acquisition of Karuna Therapeutics, Inc., marking a significant expansion...
Immunis Chairman Dr. Hans Keirstead Presents Abundance360 Moonshot
Immunis, Inc., an innovative biotech firm, announced that its Chairman, Dr. Hans Keirstead, will present at the prestigious Abundance360...
FDA Approves Breyanzi® as First CAR-T Therapy for CLL/SLL
Bristol Myers Squibb announced the accelerated FDA approval of Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR)...
Pfizer’s Phase 3 Trial Shows Positive Survival in DLBCL
Pfizer Inc. has announced promising Phase 3 study results for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and rituximab...
Merck Successfully Acquires Harpoon Therapeutics, Inc.
Merck has successfully completed the acquisition of Harpoon Therapeutics, Inc., making Harpoon a wholly-owned subsidiary of Merck. As a...
Viiv Healthcare Presents Promising Cabenuva Data at CROI
ViiV Healthcare has announced promising interim data from the LATITUDE phase III trial, presented at the CROI 2024. The...
Gilead & Merck’s Phase 2 Data Show Promise for Oral Weekly HIV Regimen
Gilead Sciences and Merck (MSD outside the U.S. and Canada) have shared promising Phase 2 clinical study results for...
Gilead & Merus Team Up for Groundbreaking T-Cell Engagers
Gilead Sciences, Inc. and Merus N.V. have entered into a research collaboration to develop novel dual tumor-associated antigen (TAA)...
EU Validates Datopotamab Apps for Lung & Breast Cancer
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan,...
Real-World Data Back Veklury for Hospitalized COVID-19 Patients
Gilead Sciences revealed new data from three retrospective studies that suggest its antiviral drug Veklury (remdesivir) not only reduces...